A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
A Phase Ⅰb/Ⅱ Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
A PHASE1/PHASE2 clinical study on Small Cell Lung Cancer, this trial is completed. The trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and has accumulated 10 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Jul 2025 — Present [monthly]
Completed PHASE1/PHASE2
Status: Unknown → Completed
-
Nov 2024 — Jul 2025 [monthly]
Unknown PHASE1/PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 5 earlier versions
-
Nov 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Unknown Status → Active Not Recruiting
-
Apr 2022 — Nov 2022 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Apr 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .